A new approach to treating inherited sight loss
A new approach to treating inherited sight loss
Search
Search results
Potential drug targets identified for RP
A recently published study has described numerous disease mechanisms that appear to be common across different types of inherited sight loss, suggesting that there is significant potential for drug treatments that could work regardless of the underlying causative gene.
Webinar: Influencing with Retina UK
The latest webinar from Retina UK.
Flipping the switch on RP: SparingVision doses patients in their first in-human clinical trial for SPVN20
The latest research news from Retina UK.
Slowing sight loss in stargardts: Ocugen’s gene therapy trial offers promising early results
Ocugen’s gene therapy candidate, OCU410ST, is an experimental treatment designed to slow vision loss in Stargardt disease, an inherited retinal disease (IRD) with no approved therapies currently.
SparingVision completes dosing in PRODYGY trial of SPVNO6 for retinitis pigmentosa.
SparingVision have announced this week that they have dosed all participants in their phase 1/2 PRODYGY clinical trial for SPVN06, a gene agnostic therapy aimed at slowing disease progression in Retinitis Pigmentosa (RP).
Skydiving
Skydiving is an exhilarating experience, and you can do this while supporting our cause. Various dates and locations are available across the UK.
Tough Mudder 2026
With various events to choose from in 2026, these hugely popular events are back for another year! Round up your friends, family members and colleagues and join #TeamRetinaUK for a fun day out!
Tough Mudder 2026 (London West)
With various events to choose from in 2026, these hugely popular events are back for another year! Round up your friends, family members and colleagues and join #TeamRetinaUK for a fun day out in 2026.
Look Forward – Winter 2023 – Issue 181
Inside this edition, register now for our AI webinar on 7 December with Dr Nikolas Pontikos.